News | Proton Therapy | September 17, 2015

ProTom International Accelerates Focus on MGH Proton Therapy Installation

Radiance 330 proton therapy system could begin treating patients at Massachusetts General Hospital in 2017

Protom International, Radiance 330, proton therapy system, MGH, Massachusetts General Hospital, installation

Image courtesy of Protom International

September 17, 2015 — ProTom International announced its accelerated focus on the installation of its Radiance 330 proton therapy system to be housed in the Massachusetts General Hospital ("MGH") Department of Radiation Oncology. For the first time, advanced scanning-beam technology is being installed inside a radiation-shielded vault embedded within an existing, operational radiation oncology department — a solution that enables the facility to share clinical staff, ancillary equipment and patient support areas.

Beginning in fall 2014, modifications were made inside two empty linear accelerator (linac) vaults that were reserved for future expansion, preparing the space for the new proton therapy suite. Adapting the technology to the space and occupancy constraints of the operational clinical facility was made possible partially due to the lower neutron emissions of the compact synchrotron accelerator. A reduction in the footprint of the treatment room due to the smaller gantry, as well as the highly-efficient scanning proton beam, have each helped reduce shielding costs in the facility. Stray radiation has a major impact on shielding requirements and facility design, and Radiance 330 has some of the lowest levels in the industry.

On site, the equipment support and alignment components have been installed, and the pre-installation utility infrastructure has been completed and accepted. Nearby, at ProTom’s assembly and test facility, equipment assembly, integration, testing and optimization are underway in preparation for installation on site. The synchrotron has been assembled and tested for all energies up to and including 330 MeV. A new, custom-designed power supply has been factory tested and demonstrated to provide power to the synchrotron for acceleration of protons to energies of up to 330 MeV, ensuring that the system is “future-ready,” having already been prepped for proton radiography techniques.

ProTom is currently working on the Radiance 330’s interface with a new combined 2-D/3-D imaging and positioning system. The system, selected by the hospital, features a cone beam computed tomography (CT) image guidance ring atop a custom-designed robotic patient positioner. The system will be controlled through Radiance 330 workflow management software for seamless automation of clinical operation. Over the past several months ProTom has commenced design of its own hand pendant for system control, which shall be honed to accommodate user input and MGH-specific functionality. The pendant interfaces with ProTom’s software governing workflow management and motion control. ProTom’s proprietary Treatment Delivery Control System (TDCS) shall interface directly with MGH’s in-house information and workflow management software (Whiteboard).

ProTom’s accelerated focus on the MGH project comes after successfully completing its restructuring and recapitalization as offered through the Chapter 11 process, and throughout the reorganization MGH has sustained its full support to ProTom for successful project completion. The new MGH proton facility is expected to be completed and could begin treating patients in 2017.

For more information:

Related Content

Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Overlay Init